angiotensin II receptor antagonist

(redirected from Angiotensin II receptor antagonists)

angiotensin II receptor antagonist

Any of a family of agents (e.g., losartan and valsartan) that block the binding of angiotensin II (A-II) to their cognate cell receptors—AT1, AT2 and others. First-generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains to block the binding of A-II to AT1.

ARAs are an alternative to ACEI therapy in patients with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference of which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.

angiotensin II receptor antagonist

Pharmacology Any of a family of agents-eg losartan and valsartan, which block the binding of angiotensin II–A-II to its cognate cell membrane receptors–AT1, AT2, and others; 1st generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains, blocking the binding of A-II to AT1; an alternative to ACEI therapy for Pts with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.
References in periodicals archive ?
Feng Y, Biocompatible in-Tube Solid-Phase Microextraction Coupled to HPLC for the Determination of Angiotensin II Receptor Antagonists in Human Plasma and Urine, J.
Neuroprotective effects of antihypertensive medication are achieved by angiotensin-converting enzyme inhibitors and diuretics, according to some authors (3), but also by angiotensin II receptor antagonists and dihydropiridines, according to other authors (4).
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension.
Angiotensin II receptor antagonists have less adverse effects than ACE inhibitors, but may still cause xerostomia, taste alteration and orthostatic hypotension.
Whereas, the exclusion criteria included patients having a current diagnosis of type 1 or type 2 diabetes mellitus, patients on antihypertensive therapy or any drug that affects blood pressure, patients with a history of hepatic, cardiac, renal or blood diseases or other diseases which may interfere with the study, patients having hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, patients with a history of severe or resistant hypertension, patients with secondary hypertension of any etiology, pregnant or breast feeding women, and patients with serious disorders which may limit the ability to evaluate the efficacy of the trial drugs.
24 October 2011 - The European Medicines Agency (EMA) said in a press release on Thursday that its Committee for Medicinal Products for Human Use (CHMP) had reviewed the possible connection between the use of angiotensin II receptor antagonists (ARBs) and the occurrence of new cancers and concluded that the evidence does not support any increased risk of cancer in patients using these medicines.
There is need to test a potential additive effect of a low protein diet in combination with angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists or other antiproteinuric medications.
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.
Other medications commonly used to treat hypertension include beta blockers such as atenolol (Tenormin), calcium channel blockers such as amlodipine (Norvasc), angiotensin II receptor antagonists such as losartan (Cozaar), and angiotensin-converting enzyme (ACE) inhibitors such as fosinopril (Monopril).
It should be used with caution in women on other medications that can increase potassium, including NSAIDs, potassium-sparing diuretics, ACE inhibitors, or angiotensin II receptor antagonists.

Full browser ?